THE DEVELOPMENT PROGRAMME
Reta-B1 analytical, stability and safety programme
Reta-B1 remains subject to analytical, pharmaceutical, toxicological and clinical evaluation. The programme is organised as nine development pillars; each pillar owns a question the formulation must answer before any stronger claim can be made. None of the pillars reports completed results on this site.
- 1
Identity and purity
Confirmation of both active components and control of impurities in each layer of the dual-layer cake.
- 2
Dual-layer formation and reproducibility
Physical integrity of the two-layer architecture, batch to batch: layer definition, interface sharpness, cake structure.
- 3
Interlayer separation
Migration between the retatrutide and thiamine layers during freezing, lyophilisation and storage.
- 4
Lyophilisation behaviour
Cycle performance for the co-lyophilised cake: residual moisture, appearance, structural uniformity.
- 5
0.5 mL P-EARLs™ reconstitution performance
Reconstitution time and completeness, particulates, osmolality and the pH of the reconstituted preparation.
- 6
pH, pI, ionic-strength and solubility reconciliation
The quantitative evaluation of the conflicts P-EARLs™ is engineered to reconcile.
- 7
Retatrutide and thiamine stability
Component stability across manufacture and storage, including thiamine degradation, oxidation and light sensitivity.
- 8
Route and tissue compatibility
Subcutaneous local tolerance and post-reconstitution hold time of the unified preparation.
- 9
Pharmacokinetic and nutritional evaluation
Whether the formulation affects retatrutide pharmacokinetics or activity, and whether a weekly thiamine component can meaningfully support thiamine status.
Measuring thiamine status
The nutritional pillar has a defined measurement toolkit. Whole-blood thiamine pyrophosphate by LC-MS/MS carries published healthy-adult reference intervals of 101–189 nmol/L (Stidsen et al., 2024), and erythrocyte transketolase activity (ETKAC) provides a functional readout; the reference literature is explicit that no single agreed biomarker exists (Whitfield et al., 2018). Dose justification for the 20 mg inclusion, and any future replenishment claim, will be argued from these measurements — not asserted from the label.
- Stidsen et al., 2024 — LC-MS/MS whole-blood TPP reference intervals ↗
Supports: the analytical yardstick for thiamine status. Does not prove: deficiency thresholds in GLP-1 users.
- Whitfield et al., 2018 — thiamine biomarkers and their limits ↗
Supports: the biomarker options and their interpretation limits. Does not prove: any supplementation protocol.